National Pharmacy Health & Leadership Alliance Verify a MemberMember Login
NPHLANational Pharmacy Health & Leadership Alliance
Apply for Membership

02RegulatoryNPHLA Explains

503A or 503B? How the two federal compounding pathways differ — and why it mattered for GLP-1 medicines

Federal law gives compounders two routes, with different rules on prescriptions, quality standards, oversight and copies of approved drugs. Here is how they compare, using GLP-1 compounding as the worked example.

By NPHLA IntelligencePublished AI-assisted · Editor reviewed

The signal

Federal law recognizes two compounding pathways: section 503A, for state-licensed pharmacies and physicians compounding for identified patients, and section 503B, for registered outsourcing facilities that must meet current good manufacturing practice requirements.

Why this matters

The pathway determines whether a patient-specific prescription is needed, which quality requirements apply, how FDA oversees the compounder and when copies of approved drugs may be made — the questions at the center of GLP-1 compounding as those medicines moved onto and off FDA’s drug shortage list.

The 2-minute brief

Section 503A is the traditional pharmacy-compounding pathway: a licensed pharmacist or physician compounds for an identified patient on a valid prescription, and the drug can be exempt from FDA approval, CGMP and some labeling requirements when the section’s conditions are met.

Section 503B, added in 2013, created outsourcing facilities. They register with FDA, must follow CGMP, are inspected by FDA and report adverse events and products — and they may supply compounded drugs in response to orders from health care providers, without patient-specific prescriptions.

For GLP-1 medicines the difference became practical when FDA’s drug shortage list changed. Both pathways restrict copies of approved drugs, but the restrictions relax while a drug is in shortage and return when FDA resolves the shortage, as FDA has determined for tirzepatide and semaglutide injection products.

What changed

  1. Section 503A covers compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, and requires that drugs be compounded on the basis of valid patient-specific prescriptions.[1]
  2. When its conditions are met, section 503A exempts compounded drugs from FDA approval, current good manufacturing practice (CGMP) requirements and the requirement for adequate directions for use.[1]
  3. Section 503B, created by the Drug Quality and Security Act in 2013, established outsourcing facilities: compounders of sterile drugs that register with FDA.[1, 2]
  4. Outsourcing facilities must comply with CGMP requirements, are inspected by FDA on a risk-based schedule, report adverse events and give FDA information about the products they compound.[2]
  5. An outsourcing facility may distribute compounded drugs pursuant to a patient-specific prescription or in response to an order from a health care provider, and is not required to be a licensed pharmacy.[1, 3]
  6. Both pathways limit compounding drugs that are essentially copies of approved or commercially available drugs, and those limits work differently while a drug is on FDA’s drug shortage list.[4]
  7. FDA has determined that the shortages of tirzepatide injection and semaglutide injection products are resolved.[5]
  8. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed.[6]

Who this affects

  • 503A compounders
  • 503B outsourcing facilities
  • Pharmacies
  • Pharmacists
  • Prescribers
  • Weight-management clinics
  • Med spas

What to watch next

FDA statements on GLP-1 compounding and changes to the drug shortage list, which determine when shortage-related flexibilities apply.[5]

FDA decisions on which bulk drug substances outsourcing facilities may use.[3]

NPHLA takeaway

The legal pathway, not the product name, decides the rules. Before relying on a compounded GLP-1 product, pharmacies, prescribers and clinics should confirm whether it was made under section 503A or 503B and check FDA’s current shortage status and statements. This is general information, not legal advice.

Source file

  1. [1]
    Human Drug Compounding Laws

    Primary sourceU.S. Food and Drug Administration

  2. [2]
    Information for Outsourcing Facilities

    Primary sourceU.S. Food and Drug Administration

  3. [3]
  4. [4]
  5. [5]
  6. [6]

Drafted with AI assistance from the sources listed in the Source File, then reviewed and approved by an NPHLA editor before publication. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.